These data are in accord with the experimental and clinical evidence that BCR-ABL and JAK2 V617F oncogenes in CML and PV, respectively, have different transforming properties. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.